In the constantly developing field of medical technology, the Extracorporeal Membrane Oxygenation Machine Market has developed into a revolutionary tool in critical care. These life-supporting devices can provide temporary respiratory and/or cardiac support to patients with severe heart or lung failure. The ECMO system, which functions as an external lung or heart, oxygenates the patient’s blood and removes carbon dioxide, allowing their organs to rest and recover. The phenomenal expansion of the global market for ECMO devices is being driven by advancements in technology, more awareness, and an increase in respiratory and cardiac diseases.
ECMO machines, which were primarily used in paediatric settings when they were first used, are today used by newborns, kids, and adults alike. In addition to providing cardiac and respiratory support, they are now also employed for ECMO-assisted organ transplant procedures, the treatment of acute respiratory distress syndrome (ARDS), COVID-19-related respiratory failure, and the management of trauma-induced lung injury.
Get Your Copy: Uncover the Massive Market Potential of Extracorporeal Membrane Oxygenation Machine Market – Our Sample Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-14300
Extracorporeal membrane oxygenation machine sales were estimated at US$ 531 million in 2021. From 2022 to 2032, the market is projected to grow steadily at a CAGR of 5%, reaching US$ 908 billion by the end of that year.
The market for ECMO machines has shown tremendous growth in recent years and is anticipated to keep growing quickly. The frequency of respiratory and cardiac disorders, the ageing of the population, and the increased need for sophisticated life-support systems are all factors that are fueling this expansion. Additionally, it is anticipated that ongoing research and development activities in ECMO technology would further improve its capabilities and stimulate market growth.
Key Takeaways:
- By application, high demand for early diagnosis and diagnostic imaging, and technological advancements in the extracorporeal membrane oxygenation machine market are expected to propel the respiratory segment to the top.
- The arterio-venous segment is likely to hold the majority of the market based on modality owing to the benefits associated with this technology segment, such as effective dynamic range, thereby boosting the ECMO systems market growth.
- Based on patient type, the adult segment is projected to lead the market as the global burden of cardiac and respiratory diseases in adults is rising due to increased consumption of alcohol, tobacco, smoking, and a sedentary lifestyle.
Because of the presence of major players and the rising number of product launches, government support for high-quality healthcare, which is also seen as one of the key trends in the ECMO systems market, and the rising prevalence of diseases in the United States and Canada, such as chronic obstructive pulmonary disease, which increases hospital admission and is favoured by reimbursement policies, the North American market is anticipated to lead the ECMO systems market. an FMI analyst claims.
Competitive Landscape:
- Medtronic plc (USA),
- Fresenius Medical Care A.G. & Co. KGAA (Germany),
- Getinge Group (Sweden),
- Microport (China),
- Origin Biomedical (USA),
- Terumo Cardiovascular Systems Corporation,
- Livanova plc (United Kingdom),
- Nipro Corporation (Japan),
- Euro sets S.R.L. (Italy),
- Cytosorbents Corporation (Australia),
- Abiomed
Major global players produce the majority of ECMO support systems. Market leaders have established their position by investing more in research and having a better distribution system.
To stay competitive in the market, extracorporeal membrane oxygenation machines manufacturers are actively involved in product launches and technological innovation.
- ALung Technologies, Inc. has begun commercialization of its ground-breaking next-generation artificial lung. The device is based on University of Pittsburgh intellectual property licensed to ALung Technologies, Inc.
- Medtronic has released its artificial lung therapy for the treatment of COVID-19. An artificial pump that pumps blood from a person’s body to an oxygenator is called ECMO, and it also has an FDA-approved device for ECMO procedures lasting up to 6 hours.
Gain Valuable Insights Through Our Cutting-Edge Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14300
Key Segments:
By Product:
- ECMO Machines
- Portable Devices
- Static Devices
- Software
By Service Type:
- Application
- Middleware
- Infrastructure
By Component:
- Pumps
- Oxygenators
- Controllers
- Cannul
- Assessories
By Modality:
- Veno-Venous
- Veno-Arterials
- Arterio-Venous
By Patient Type:
- Neonates
- Pediatrics
- Adults
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
